Sakshaug, B. Cristoffer
Folkesson, Evelina
Haukaas, Tonje Husby
Visnes, Torkild
Flobak, Åsmund
Funding for this research was provided by:
Liaison Committee between the Central Norway Regional Health Authority (Samarbeidsorganet) and the Norwegian University of Science and Technology
Norges Forskningsråd (310160)
The Research Council of Norway, under the framework of the European Research Area (ERA) PerMed program (32509)
The NTNU Strategic Research Area NTNU Health
NTNU Norwegian University of Science and Technology
Article History
Received: 23 September 2022
Accepted: 18 October 2023
First Online: 23 October 2023
Competing interests
: The corresponding author has received honoraria from pharmaceutical companies Bayer, Novartis, Pfizer, Pierre Fabre, Amgen, and regularly interacts with major pharmaceutical companies in Norway in the CONNECT consortium (ExternalRef removed), but we do not see that this should influence the interpretation of our findings. The other authors declare no conflicts of interest.